{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:44:39Z","timestamp":1790415879657,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2025.103321","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:58:29Z","timestamp":1767110309000},"page":"103321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6365-2899","authenticated-orcid":false,"given":"Priyanka","family":"Raheja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Lemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Monahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Le Quellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103321_bib1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103321_bib2","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1182\/blood-2024-200008","article-title":"Burden of treatment on people with hemophilia: global real-world data","volume":"144","author":"Jim\u00e9nez-Yuste","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103321_bib3","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.rpth.2025.103321_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/JBM.S490588","article-title":"Emerging therapies in hemophilia: improving equitable access to care","volume":"16","author":"Lewandowska","year":"2025","journal-title":"J Blood Med"},{"key":"10.1016\/j.rpth.2025.103321_bib5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1089\/hum.2023.134","article-title":"Prevalent and disseminated recombinant and wild-type adeno-associated virus integration in macaques and humans","volume":"34","author":"Martins","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.rpth.2025.103321_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMc2509703","article-title":"AAV gene therapy in severe hemophilia B","volume":"393","author":"Miesbach","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103321_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.rpth.2025.103321_bib8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1128\/JVI.73.2.939-947.1999","article-title":"Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses","volume":"73","author":"Bantel-Schaal","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.rpth.2025.103321_bib9","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1128\/JVI.00867-13","article-title":"Structural insights into adeno-associated virus serotype 5","volume":"87","author":"Govindasamy","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.rpth.2025.103321_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/v13010101","article-title":"Completion of the AAV structural atlas: serotype capsid structures reveals clade-specific features","volume":"13","author":"Mietzsch","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.rpth.2025.103321_bib11","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.rpth.2025.103321_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.rpth.2025.103321_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.rpth.2025.103321_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ymthe.2005.08.017","article-title":"Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates","volume":"13","author":"Gao","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2025.103321_bib15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103321_bib16","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.103321_bib17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103321_bib18","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/bloodadvances.2024015291","article-title":"Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years","volume":"9","author":"von Drygalski","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103321_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101568","article-title":"Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study","volume":"33","author":"Klamroth","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.rpth.2025.103321_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41434-024-00441-5","article-title":"Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia","volume":"31","author":"Pabinger","year":"2024","journal-title":"Gene Ther"},{"key":"10.1016\/j.rpth.2025.103321_bib21","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","article-title":"Adeno-associated virus-based gene therapy for hemophilia A and B: a systematic review and meta-analysis","volume":"8","author":"Deshpande","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103321_bib22","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ymthe.2025.03.043","article-title":"Gene therapy for hemophilia \u2013 from basic science to first approvals of \u201cone-and-done\u201d therapies","volume":"33","author":"Herzog","year":"2025","journal-title":"Mol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2025.103321_bib23","article-title":"Efficacy safety and quality of life 5 years after valoctocogene roxaparvovec gene transfer","volume":"9","author":"Leavitt","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103321_bib24","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103321_bib25","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.103321_bib26","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103321_bib27","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","article-title":"Sustained clinical benefit of AAV gene therapy in severe hemophilia B","volume":"392","author":"Reiss","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103321_bib28","article-title":"The WFH guidelines for the management of haemophilia: AAV gene therapy, 2025","author":"Pierce","year":"2025","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:54:46Z","timestamp":1778896486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925006454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2475037925006454"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103321","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103321"}}